Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN
Status:
RECRUITING
Trial end date:
2028-10-30
Target enrollment:
Participant gender:
Summary
This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD123 CAR-NK in the treatment of patients with relapsed/refractory acute myeloid leukemia or blastic plasma cell like dendritic cell tumors.